Brief: Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity Of A Her3 Targeted Radiotherapy At AACR
11/04/2022 12:38
April 11 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS HIGHLIGHTS POTENT ANTI-TUMOR
ACTIVITY
OF A HER3 TARGETED RADIOTHERAPY AT AACR
* ACTINIUM - DATA SHOW ENHANCED ANTITUMOR EFFECTS AND
IMPROVED
SURVIVAL WERE OBSERVED IN A PRECLINICAL NSCLC MODEL COMPARED TO
A NAKED HER3 ANTIBODY
* ACTINIUM - DATA SUPPORTS CO'S RESEARCH COLLABORATION WITH
AVEO
ONCOLOGY TO DEVELOP AND ADVANCE A HER3 TARGETED RADIOTHERAPY TO
CLINICAL STUDIES
Source text for Eikon: ID:nPn6QKzxga
Further company coverage: ATNM.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities